您的位置: 首页 > 农业专利 > 详情页

Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs as adjunctive treatments with anticancer agents
专利权人:
Administrators of the Tulane Educational Fund
发明人:
Li, Min,Maderdrut, Jerome L.,Coy, David H.,Batuman, Vecihi
申请号:
AU2009296456
公开号:
AU2009296456B2
申请日:
2009.09.25
申请国别(地区):
AU
年份:
2016
代理人:
摘要:
This invention relates to methods and compositions for the treatment, management or prevention of injuries to one or more of the organs of the body, such as the brain, heart, lung, kidneys, liver, and gastrointestinal tract, of humans or other mammals caused by one or more anticancer agents. The methods of this invention consist of the administration of an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP/VIP receptors, including all of their various isoforms. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents useful for the treatment, management or prevention of injuries to the organs of the body of humans or other mammals undergoing cancer chemotherapy. Combination therapy with one or more PACAP-like compounds plus one or more anticancer agents can be used in the treatment of hematological cancers.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充